Detalhe da pesquisa
1.
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
N Engl J Med
; 386(6): 531-543, 2022 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34910859
2.
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
N Engl J Med
; 385(13): 1172-1183, 2021 09 23.
Artigo
Inglês
| MEDLINE | ID: mdl-34192426
3.
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1899-1909, 2021 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-33951374
4.
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
J Infect Dis
; 228(6): 734-741, 2023 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37210741
5.
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
N Engl J Med
; 383(5): 415-425, 2020 07 30.
Artigo
Inglês
| MEDLINE | ID: mdl-32726528
6.
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
PLoS Med
; 18(10): e1003769, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34597298
7.
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373.
N Engl J Med
; 388(9): 857-859, 2023 Mar 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36734884
8.
Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
Antimicrob Agents Chemother
; 62(11)2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30150460
9.
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
J Infect Dis
; 216(11): 1362-1370, 2017 12 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29029260
10.
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
Antimicrob Agents Chemother
; 61(3)2017 03.
Artigo
Inglês
| MEDLINE | ID: mdl-27956428
11.
A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers.
Biologicals
; 50: 81-86, 2017 11.
Artigo
Inglês
| MEDLINE | ID: mdl-28844541
12.
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Vaccine
; 41(29): 4280-4286, 2023 06 29.
Artigo
Inglês
| MEDLINE | ID: mdl-37271706
13.
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
Sci Rep
; 13(1): 19176, 2023 11 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37932354
14.
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
JAMA Netw Open
; 6(4): e239135, 2023 04 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37099299
15.
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine.
Sci Transl Med
; 14(676): eade0424, 2022 12 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36542692
16.
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
Lancet Respir Med
; 10(2): 167-179, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34800364
17.
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial.
medRxiv
; 2022 Sep 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36172135
18.
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.
bioRxiv
; 2021 Jan 29.
Artigo
Inglês
| MEDLINE | ID: mdl-33532764
19.
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
Lancet Infect Dis
; 21(9): 1313-1323, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33894131
20.
A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of age.
Vaccine
; 38(5): 1001-1008, 2020 01 29.
Artigo
Inglês
| MEDLINE | ID: mdl-31796225